Figure 1
Figure 1. Jak2V617F disease-initiating cells are contained exclusively in the LT-HSC compartment. (A) The percentage of donor chimerism assessed in peripheral blood of lethally irradiated WT recipients of Jak2+/VFE2Acre+ LT-HSCs or a combination of Jak2+/VFE2Acre+ ST-HSCs and MPPs (mean ± SEM, n = 3-5 in each group). (B) Hematocrit of recipients of Jak2+/VFE2Acre+ LT-HSCs or a combination of Jak2+/VFE2Acre+ ST-HSCs and MPPs (mean ± SEM, n = 3-5 in each group). (C) WBC count of recipients of Jak2+/VFE2Acre+ LT-HSCs or a combination of Jak2+/VFE2Acre+ ST-HSCs and MPPs (mean ± SEM, n = 3-5 in each group). (D) Platelet count of recipients of Jak2+/VFE2Acre+ LT-HSCs or a combination of Jak2+/VFE2Acre+ ST-HSCs and MPPs (mean ± SEM, n = 3-5 in each group). (E) The percentage of Jak2+/VF(VF) donor chimerism assessed in CD150+CD48− LSK cells (LT-HSCs) from mice transplanted with Jak2+/VF LT-HSC cells or Jak2+/VF ST-HSC + MPP cells (mean ± SEM, n = 3-4 in each group).

Jak2V617F disease-initiating cells are contained exclusively in the LT-HSC compartment. (A) The percentage of donor chimerism assessed in peripheral blood of lethally irradiated WT recipients of Jak2+/VFE2Acre+ LT-HSCs or a combination of Jak2+/VFE2Acre+ ST-HSCs and MPPs (mean ± SEM, n = 3-5 in each group). (B) Hematocrit of recipients of Jak2+/VFE2Acre+ LT-HSCs or a combination of Jak2+/VFE2Acre+ ST-HSCs and MPPs (mean ± SEM, n = 3-5 in each group). (C) WBC count of recipients of Jak2+/VFE2Acre+ LT-HSCs or a combination of Jak2+/VFE2Acre+ ST-HSCs and MPPs (mean ± SEM, n = 3-5 in each group). (D) Platelet count of recipients of Jak2+/VFE2Acre+ LT-HSCs or a combination of Jak2+/VFE2Acre+ ST-HSCs and MPPs (mean ± SEM, n = 3-5 in each group). (E) The percentage of Jak2+/VF(VF) donor chimerism assessed in CD150+CD48 LSK cells (LT-HSCs) from mice transplanted with Jak2+/VF LT-HSC cells or Jak2+/VF ST-HSC + MPP cells (mean ± SEM, n = 3-4 in each group).

Close Modal

or Create an Account

Close Modal
Close Modal